---
title: "Zhejiang Medicine Co.,Ltd. (600216.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600216.SH.md"
symbol: "600216.SH"
name: "Zhejiang Medicine Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T17:00:01.546Z"
locales:
  - [en](https://longbridge.com/en/quote/600216.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600216.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600216.SH.md)
---

# Zhejiang Medicine Co.,Ltd. (600216.SH)

## Company Overview

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.zmc.top](https://www.zmc.top) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 89 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -6.03% |  |
| Net Profit YoY | -48.54% |  |
| P/B Ratio | 1.21 |  |
| Dividend Ratio | 2.59% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 13631377318.21 |  |
| Revenue | 8831758609.49 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.74% | C |
| Profit Margin | 8.52% | B |
| Gross Margin | 35.06% | C |
| Revenue YoY | -6.03% | D |
| Net Profit YoY | -48.54% | D |
| Total Assets YoY | 1.30% | C |
| Net Assets YoY | 0.88% | C |
| Cash Flow Margin | 223.72% | B |
| OCF YoY | -6.03% | D |
| Turnover | 0.63 | B |
| Gearing Ratio | 19.84% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhejiang Medicine Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-6.03%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-48.54%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.21",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.59%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "13631377318.21",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8831758609.49",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.74%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "8.52%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "35.06%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-6.03%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-48.54%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.30%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.88%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "223.72%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-6.03%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.63",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "19.84%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 17.73 | 33/215 | 12.39 | 10.76 | 9.74 |
| PB | 1.18 | 16/215 | 1.37 | 1.29 | 1.22 |
| PS (TTM) | 1.51 | 24/215 | 1.63 | 1.56 | 1.49 |
| Dividend Yield | 2.65% | 44/215 | 2.58% | 2.44% | 2.24% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-12T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |
| Hold | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.85 |
| Highest Target | 18.50 |
| Lowest Target | 16.70 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600216.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600216.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600216.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600216.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**